Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D’amico Risk Groups in A Contemporary Cohort
Mario de Angelis , Carolin Siech , Letizia Maria Ippolita Jannello , Francesco Di Bello , Natali Rodriguez Peñaranda , Pietro Scilipoti , Mattia Longoni , Jordan A. Goyal , Zhe Tian , Nicola Longo , Ottavio de Cobelli , Gennaro Musi , Felix K.H. Chun , Stefano Puliatti , Fred Saad , Shahrokh F. Shariat , Giorgio Gandaglia , Marco Moschini , Francesco Montorsi , Alberto Briganti , Pierre I. Karakiewicz
{"title":"Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D’amico Risk Groups in A Contemporary Cohort","authors":"Mario de Angelis , Carolin Siech , Letizia Maria Ippolita Jannello , Francesco Di Bello , Natali Rodriguez Peñaranda , Pietro Scilipoti , Mattia Longoni , Jordan A. Goyal , Zhe Tian , Nicola Longo , Ottavio de Cobelli , Gennaro Musi , Felix K.H. Chun , Stefano Puliatti , Fred Saad , Shahrokh F. Shariat , Giorgio Gandaglia , Marco Moschini , Francesco Montorsi , Alberto Briganti , Pierre I. Karakiewicz","doi":"10.1016/j.clgc.2025.102429","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>External beam radiation therapy (EBRT) predisposes to radiation-induced bladder (BCa) and/or rectal cancer (RCa). This risk may have declined with modern radiation techniques. Moreover, it remains unclear whether the risk varies by age or D’Amico risk classification.</div></div><div><h3>Materials and Methods</h3><div>Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients who were treated with either EBRT or radical prostatectomy (RP) for prostate cancer. Cumulative incidence plots and competing risks regression (CRR) models were fitted. Subgroup analyses were performed according to year of diagnosis (contemporary: 2012-2020 vs. historical: 2004-2011 cohorts), age (< 65 vs. ≥ 65) and D’Amico risk groups.</div></div><div><h3>Results</h3><div>Of 251,838, 110,239 (44%) underwent EBRT versus 141,599 RP (56%). Relative to RP patients, EBRT was associated with a two-fold higher 10-year incidence of secondary BCa (0.9 versus 1.9%, respectively). In multivariable CRR models, EBRT was associated with higher risk of BCa (HR: 1.5, 95% CI: 1.3-1.6, <em>P</em> < .001). Similarly, relative to RP, EBRT was also associated with two-fold higher 10-year incidence of secondary RCa (0.8 versus 1.5%, respectively). In multivariable CRR models, EBRT was associated with higher risk of RCa (HR: 1.4, 95% CI: 1.2-1.5, <em>P</em> < .001). In subgroup analyses, the 5-year EBRT–RP absolute difference in secondary RCa was lower in the contemporary cohort (0.2%) than in the historical cohort (0.5%), whereas no such reduction was observed for BCa. In subgroup analyses according to D’Amico risk groups and age, no clinically significant differences were recorded.</div></div><div><h3>Conclusion</h3><div>EBRT is associated with higher risk of both BCa and RCa as compared to RP. In contemporary EBRT patients, secondary RCa rate is lower, but not BCa rate. D’Amico risk groups as well as age categories did not affect either secondary BCa or secondary RCa rates.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 6","pages":"Article 102429"},"PeriodicalIF":2.4000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325001296","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
External beam radiation therapy (EBRT) predisposes to radiation-induced bladder (BCa) and/or rectal cancer (RCa). This risk may have declined with modern radiation techniques. Moreover, it remains unclear whether the risk varies by age or D’Amico risk classification.
Materials and Methods
Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients who were treated with either EBRT or radical prostatectomy (RP) for prostate cancer. Cumulative incidence plots and competing risks regression (CRR) models were fitted. Subgroup analyses were performed according to year of diagnosis (contemporary: 2012-2020 vs. historical: 2004-2011 cohorts), age (< 65 vs. ≥ 65) and D’Amico risk groups.
Results
Of 251,838, 110,239 (44%) underwent EBRT versus 141,599 RP (56%). Relative to RP patients, EBRT was associated with a two-fold higher 10-year incidence of secondary BCa (0.9 versus 1.9%, respectively). In multivariable CRR models, EBRT was associated with higher risk of BCa (HR: 1.5, 95% CI: 1.3-1.6, P < .001). Similarly, relative to RP, EBRT was also associated with two-fold higher 10-year incidence of secondary RCa (0.8 versus 1.5%, respectively). In multivariable CRR models, EBRT was associated with higher risk of RCa (HR: 1.4, 95% CI: 1.2-1.5, P < .001). In subgroup analyses, the 5-year EBRT–RP absolute difference in secondary RCa was lower in the contemporary cohort (0.2%) than in the historical cohort (0.5%), whereas no such reduction was observed for BCa. In subgroup analyses according to D’Amico risk groups and age, no clinically significant differences were recorded.
Conclusion
EBRT is associated with higher risk of both BCa and RCa as compared to RP. In contemporary EBRT patients, secondary RCa rate is lower, but not BCa rate. D’Amico risk groups as well as age categories did not affect either secondary BCa or secondary RCa rates.
期刊介绍:
Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.